Two kinds of hypoglycemic drugs are very effective in colorectal cancer

Share This Post

Obesity is on the rise worldwide and is related to the incidence of colon cancer , but its mechanism has been a mystery. In a new study, Yale University research discovered how obesity drives tumor growth in mice and revealed potential strategies to combat this cancer pathogenesis.

The team studied mice implanted with genetic models of tumors or colon cancer. The researchers first studied the effect of a high-fat diet on mice. Then they gave the mice one of two drugs: one was the controlled release mitochondrial proton mass (CRMP), and the other was metformin (the world’s most commonly used diabetes prescription drug), which burns fat in the liver drug.

The team found that high levels of insulin are the link between obesity and colon cancer. Insulin increases glucose uptake in tumors and  promotes tumor growth. The  researchers also found that both drugs can reduce insulin levels and slow tumor growth in mice.

The researchers say that this study is the first to demonstrate that obesity-induced high insulin levels drive colon cancer by increasing glucose uptake in these models. Although further research is needed to confirm whether these findings are applicable to humans, insulin reduction therapy: metformin, CRMP , And even exercise can help slow or prevent colon cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy